Loading clinical trials...
Loading clinical trials...
Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Eligible for Intensive Induction Chemotherapy
Conditions
Interventions
Olutasidenib
Venetoclax
+1 more
Locations
1
United States
University of Miami
Miami, Florida, United States
Start Date
March 31, 2026
Primary Completion Date
March 31, 2029
Completion Date
March 31, 2029
Last Updated
April 16, 2026
NCT05564390
NCT07320235
NCT07523555
NCT07295951
NCT06284486
NCT05768932
Lead Sponsor
Justin Watts, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions